Cargando…
Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand
Objective: The aim of this study was to evaluate the cost-effectiveness of different glucosamine formulations and preparations used for the management of osteoarthritis in Thailand compared with placebo. Methods: We used a validated model to simulate the individual patient Utility score from aggrega...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059797/ https://www.ncbi.nlm.nih.gov/pubmed/36976312 http://dx.doi.org/10.3390/medicines10030023 |
_version_ | 1785016960618070016 |
---|---|
author | Bruyère, Olivier Detilleux, Johann Reginster, Jean-Yves |
author_facet | Bruyère, Olivier Detilleux, Johann Reginster, Jean-Yves |
author_sort | Bruyère, Olivier |
collection | PubMed |
description | Objective: The aim of this study was to evaluate the cost-effectiveness of different glucosamine formulations and preparations used for the management of osteoarthritis in Thailand compared with placebo. Methods: We used a validated model to simulate the individual patient Utility score from aggregated data available from 10 different clinical trials. We then used the Utility score to calculate the quality-adjusted life year (QALY) over 3 and 6 months treatment period. We used the public costs of glucosamine products available in Thailand in 2019 to calculate the incremental cost-effectiveness ratio. We separated the analyses for prescription-grade crystalline glucosamine sulfate (pCGS) and other formulations of glucosamine. A cost-effectiveness cut-off of 3.260 USD/QALY was considered. Results: Irrespective of the glucosamine preparation (tablet or powder/capsule), the data show that pCGS is cost-effective compared with placebo over a 3 and 6 months. However, the other glucosamine formulations (e.g., glucosamine hydrochloride) never reached the breakeven point at any time. Conclusions: Our data show that pCGS is cost-effective for the management of osteoarthritis in the Thai context while other glucosamine formulations are not. |
format | Online Article Text |
id | pubmed-10059797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100597972023-03-30 Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand Bruyère, Olivier Detilleux, Johann Reginster, Jean-Yves Medicines (Basel) Article Objective: The aim of this study was to evaluate the cost-effectiveness of different glucosamine formulations and preparations used for the management of osteoarthritis in Thailand compared with placebo. Methods: We used a validated model to simulate the individual patient Utility score from aggregated data available from 10 different clinical trials. We then used the Utility score to calculate the quality-adjusted life year (QALY) over 3 and 6 months treatment period. We used the public costs of glucosamine products available in Thailand in 2019 to calculate the incremental cost-effectiveness ratio. We separated the analyses for prescription-grade crystalline glucosamine sulfate (pCGS) and other formulations of glucosamine. A cost-effectiveness cut-off of 3.260 USD/QALY was considered. Results: Irrespective of the glucosamine preparation (tablet or powder/capsule), the data show that pCGS is cost-effective compared with placebo over a 3 and 6 months. However, the other glucosamine formulations (e.g., glucosamine hydrochloride) never reached the breakeven point at any time. Conclusions: Our data show that pCGS is cost-effective for the management of osteoarthritis in the Thai context while other glucosamine formulations are not. MDPI 2023-03-08 /pmc/articles/PMC10059797/ /pubmed/36976312 http://dx.doi.org/10.3390/medicines10030023 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bruyère, Olivier Detilleux, Johann Reginster, Jean-Yves Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand |
title | Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand |
title_full | Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand |
title_fullStr | Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand |
title_full_unstemmed | Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand |
title_short | Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand |
title_sort | health technology assessment of different glucosamine formulations and preparations currently marketed in thailand |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059797/ https://www.ncbi.nlm.nih.gov/pubmed/36976312 http://dx.doi.org/10.3390/medicines10030023 |
work_keys_str_mv | AT bruyereolivier healthtechnologyassessmentofdifferentglucosamineformulationsandpreparationscurrentlymarketedinthailand AT detilleuxjohann healthtechnologyassessmentofdifferentglucosamineformulationsandpreparationscurrentlymarketedinthailand AT reginsterjeanyves healthtechnologyassessmentofdifferentglucosamineformulationsandpreparationscurrentlymarketedinthailand |